The present invention relates to crystalline forms of cis-(E)-4-(3-Fluorophenyl)-2&prime；,3&prime；,4&prime；,9&prime；-tetrahydro-N,N-dimethyl-2&prime；-(1-oxo-3-phenyl-2-propenyl)-spiro[cyclohexane-1,1&prime；[1H]-pyrido[3,4-b]indol]-4-amine, pharmaceutical compositions and medicaments comprising these modifications, the use of these modifications as well as to a process for making the crystalline forms.L'invention concerne des formes cristallines de cis-(E)-4-(3-fluorophényl)-2',3',4',9'- tétrahydro-N,N-diméthyl-2'-(1-oxo-3-phényl-2-propényl)-spiro[cyclohexane-1, 1 '[1 H]- pyrido[3,4-b]indol]-4-amine, des compositions pharmaceutiques et des médicaments comprenant ces modifications, l'utilisation de ces modifications, ainsi qu'un procédé de production desdites formes cristallines.
